高盛将泰格医药股票评级从中性上调至买入。

Core Viewpoint - Goldman Sachs upgraded Tiger Med's stock rating from Neutral to Buy [1] Group 1 - The upgrade reflects a positive outlook on Tiger Med's future performance [1]